Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera®/Rituxan®) in Patients With Active Rheumatoid Arthritis

NCT02093026 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02093026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02093026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera®/Rituxan®) in Patients With Active Rheumatoid Arthritis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2002
Completion date
December 31, 2012
Enrollment
465 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis